High-dose lymphoablative therapy (HDLT) with or without autologous stem-cell rescue for treatment of severe autoimmune diseases.  [electronic resource] 

 -  Tecnologica. MAP supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel  Dec 2001 
 - 29-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antilymphocyte Serum--administration & dosage<br/>Autoimmune Diseases--mortality<br/>Blue Cross Blue Shield Insurance Plans<br/>Cyclophosphamide--administration & dosage<br/>Hematopoietic Stem Cell Transplantation--adverse effects<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Insurance Coverage<br/>Technology Assessment, Biomedical<br/>Transplantation, Autologous<br/>Treatment Outcome<br/>United States<br/>United States Food and Drug Administration